High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

[1]  C. Akdis,et al.  TH17 cells in the big picture of immunology. , 2007, The Journal of allergy and clinical immunology.

[2]  D. Mancini,et al.  Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. , 2007, Transplant immunology.

[3]  C. Foster,et al.  Biological response modifier therapy for refractory childhood uveitis , 2007, British Journal of Ophthalmology.

[4]  R. Nussenblatt,et al.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 , 2007, Nature Medicine.

[5]  T. Waldmann.  Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma , 2007, Oncogene.

[6]  T. Waldmann,et al.  A Double-masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease , 2007, Ocular immunology and inflammation.

[7]  J. Preiksaitis,et al.  A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  J. Šimonek,et al.  Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. , 2007, Transplantation proceedings.

[9]  J. Figueras,et al.  Daclizumab induction and maintenance steroid‐free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Barkun,et al.  Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen vs. a standard‐dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[13]  S. Kiss,et al.  Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. , 2005, Ophthalmology.

[14]  R. Nussenblatt,et al.  Cutting Edge: In Vivo Blockade of Human IL-2 Receptor Induces Expansion of CD56bright Regulatory NK Cells in Patients with Active Uveitis , 2005, The Journal of Immunology.

[15]  R. Nussenblatt,et al.  Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. , 2005, Ophthalmology.

[16]  Andrew D. Dick,et al.  The standardization of uveitis nomenclature (SUN) working group; standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop , 2005 .

[17]  T. Waldmann,et al.  Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. , 2003, Journal of autoimmunity.

[18]  C. Foster,et al.  Treatment of ocular inflammatory disorders with daclizumab. , 2003, Ophthalmology.

[19]  S. John,et al.  IL-2 Receptor Blockade Inhibits Late, But Not Early, IFN-γ and CD40 Ligand Expression in Human T Cells: Disruption of Both IL-12-Dependent and -Independent Pathways of IFN-γ Production , 2002, The Journal of Immunology.

[20]  S. John,et al.  IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. , 2002, Journal of immunology.

[21]  M. Pescovitz,et al.  Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. , 2001, Transplantation.

[22]  D. Dunn,et al.  Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution , 2001, Annals of surgery.

[23]  T. Sasaki,et al.  A comparison of daclizumab to ATGAM induction in simultaneous pancreas‐kidney transplant recipients on triple maintenance immunosuppression , 2000, Clinical transplantation.

[24]  T. Waldmann,et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Pescovitz,et al.  Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation , 1998 .

[26]  T. Waldmann,et al.  Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. , 1997, Journal of immunology.

[27]  R. Nussenblatt,et al.  A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. , 1988, Journal of immunology.

[28]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.